Meeting
2015 ASCO Annual Meeting
A phase 1 study optimizing the dosing of olaparib tablet formulation combined with cediranib in recurrent ovarian cancer.
Authors
Joyce Liu
Dana Farber Cancer Inst, Newton, MA
Joyce Liu , Jung-min Lee , Weixiu Luo , Michael J. Birrer , Christin Whalen , Nicole D. Houston , Elizabeth Obermayer , Tatum Spagnoletti , William Thomas Barry , Elise C. Kohn , S. Percy Ivy , Ursula Matulonis
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Gynecologic Cancer
Track
Gynecologic Cancer
Sub Track
Ovarian Cancer
Clinical Trial Registration Number
NCT01116648
Citation
J Clin Oncol 33, 2015 (suppl; abstr 5559)
DOI
10.1200/jco.2015.33.15_suppl.5559
Abstract #
5559
Poster Bd #
117
Abstract Disclosures
Similar Posters
Poster
2016 ASCO Annual Meeting
Phase I study of the PD-L1 inhibitor, durvalumab (MEDI4736; D) in combination with a PARP inhibitor, olaparib (O) or a VEGFR inhibitor, cediranib (C) in Women's cancers (NCT02484404).
First Author: Jung-min Lee
Poster
2014 ASCO Annual Meeting
Biomarker correlates from the randomized phase 2 trial of the PARP inhibitor olaparib (O) with or without the antiangiogenic TKI cediranib (C) in recurrent platinum-sensitive ovarian cancer (NCT01116648).
First Author: Jung-min Lee
Poster
2020 ASCO Virtual Scientific Program
Cediranib in combination with olaparib in patients without a germline BRCA1/2 mutation with recurrent platinum-resistant ovarian cancer: Phase IIb CONCERTO trial.
First Author: Jung-Min Lee
Poster
2020 Genitourinary Cancers Symposium
Randomized phase II study of olaparib with or without cediranib in men with metastatic castration-resistant prostate cancer (mCRPC).
First Author: Joseph W. Kim